You searched for
Tag:
Therapeutic Areas
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Chiesi appoints Giuseppe Accogli as new Group CEO
27/01/2023
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
17/01/2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
04/12/2022
Chiesi Group endorses the Manifesto Against Gender-Based Violence
28/11/2022
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
21/11/2022
Chiesi tracks actions taken for a healthier, more sustainable future
14/07/2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02/05/2022
Chiesi receives positive ESG rating from independent rating agency Cerved
23/09/2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07/09/2021
New organisational order for the Chiesi Foundation
03/05/2021
Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
21/04/2021